August 10, 2023.

Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.

The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).

17 May, 2023.

Preliminary results from a University of Queensland (UQ) study to assess how the Atmo Gas Capsule compares to established SIBO (small intestinal bacterial overgrowth) diagnostic methods suggest a good correlation with duodenal aspirate and higher accuracy than a breath test.

Dr Ayesha Shah, a senior lecturer at the UQ School of Medicine, presented data from the study, led by Professor Gerald Holtmann, also from UQ, and Professor Uday Chand Ghoshal of Sanjay Gandhi Postgraduate Institute of Medical Sciences, India, in a presentation at Digestive Disease Week (DDW), held May 6-9 in Chicago.

15 May, 2023.

A Western Sydney University (WSU) and Monash University comparative study has validated the Atmo Gas Capsule relative to the SmartPill when measuring gastric emptying time and colonic transit time in patients with gastroparesis and chronic constipation.

Dr Jerry Zhou, lecturer and clinical researcher at WSU School of Medicine, presented findings from the study in a poster presentation at Digestive Disease Week  (DDW), held May 6-9 in Chicago.

1 May, 2023.

Atmo Biosciences today announced the appointment of renowned gastroenterologist Professor Eamonn Quigley as Chair of its Medical Advisory Board (MAB).

Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas. He is internationally known for his research on gastrointestinal motility disorders, particularly irritable bowel syndrome (IBS) and its link to the gut microbiome. As Atmo MAB Chair, Prof. Quigley will provide leadership and guidance regarding Atmo’s clinical trials portfolio.

“I am thrilled to have someone of Professor Quigley’s standing join our MAB as Chair,” said Atmo Biosciences CEO Malcolm Hebblewhite. “Eamonn is an internationally respected leader in gastroenterology. His ongoing research and thought leadership in the areas of motility and Small Intestinal Bacterial Overgrowth (SIBO) will be invaluable as we seek to develop these two key areas of focus in the U.S. and beyond.”